We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

168 hedge funds and large institutions have $1.42B invested in NxStage Medical Inc. in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 59 increasing their positions, 62 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $1.62M | Put options by funds: $1.28M

2% more capital invested

Capital invested by funds: $1.39B → $1.42B (+$30.6M)

5% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 62

6% less funds holding

Funds holding: 178168 (-10)

27% less funds holding in top 10

Funds holding in top 10: 118 (-3)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

Holders
168
Holders Change
-10
Holders Change %
-5.62%
% of All Funds
3.85%
Holding in Top 10
8
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-27.27%
% of All Funds
0.18%
New
15
Increased
59
Reduced
62
Closed
25
Calls
$1.62M
Puts
$1.28M
Net Calls
+$334K
Net Calls Change
+$5.53M
Name Holding Trade Value Shares
Change
Change in
Stake
ERSOT
101
Employees Retirement System of Texas
Texas
$1.07M
AIG
102
American International Group
New York
$1.03M -$54.3K -2,234 -5%
KAM
103
Kassirer Asset Management
Ontario, Canada
$994K
BCA
104
Burren Capital Advisors
Gibraltar
$875K +$40.1K +1,650 +5%
PCM
105
Prelude Capital Management
New York
$841K +$534K +21,966 +185%
Bank of America
106
Bank of America
North Carolina
$831K -$4.23M -173,927 -84%
MIM
107
MetLife Investment Management
New Jersey
$758K
VOYA Investment Management
108
VOYA Investment Management
Georgia
$719K -$14.1K -581 -2%
LCS
109
Levin Capital Strategies
New York
$712K +$697K +28,643 New
Legal & General Group
110
Legal & General Group
United Kingdom
$679K -$104K -4,261 -13%
GCL
111
Glazer Capital LLC
New York
$668K -$149K -6,139 -19%
SG Americas Securities
112
SG Americas Securities
New York
$661K +$392K +16,136 +155%
PAM
113
Panagora Asset Management
Massachusetts
$650K -$61.5K -2,530 -9%
PPA
114
Parametric Portfolio Associates
Washington
$644K +$201K +8,283 +47%
GI
115
GAMCO Investors
Connecticut
$627K +$19.5K +800 +3%
GC
116
Guggenheim Capital
Illinois
$577K +$290K +11,943 +106%
Millennium Management
117
Millennium Management
New York
$567K -$344K -14,155 -38%
CC
118
CQS Cayman
Cayman Islands
$534K +$97.3K +4,000 +23%
MLICM
119
Metropolitan Life Insurance Company (MetLife)
New York
$522K +$12.5K +515 +3%
NJBEST
120
New Jersey Better Educational Savings Trust
New Jersey
$497K
Invesco
121
Invesco
Georgia
$485K -$41.5M -1,704,930 -99%
TI
122
Telemetry Investments
New York
$447K -$97.3K -4,000 -18%
EGM
123
Engineers Gate Manager
New York
$430K +$421K +17,305 New
MWNA
124
Marshall Wace North America
New York
$385K -$12M -492,581 -97%
TRCT
125
Tower Research Capital (TRC)
New York
$370K +$362K +14,881 +70,862%

NXTM Hedge Fund Activity: Q1 2018 in Review

168 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q1 2018, worth a combined $1.42B — up 2.2% from $1.39B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of NXTM and 15 opened new positions — a net loss of 10 holders — while 62 trimmed existing stakes and 59 added.

The largest buyer was Flossbach Von Storch, opening a new position worth an estimated $72.8M. The largest seller was Invesco, cutting an estimated $41.5M.

  • 168 institutional investors held NxStage Medical Inc. (NXTM) as of Q1 2018, down from 178 in Q4 2017.
  • Funds reported $1.42B of NxStage Medical Inc. stock for Q1 2018, up 2.2% quarter-over-quarter.
  • 15 funds opened new NxStage Medical Inc. positions in Q1 2018 and 25 closed out, a net change of -10 holders.
  • The largest NxStage Medical Inc. buyer in Q1 2018 was Flossbach Von Storch, an estimated $72.8M added.
  • The largest NxStage Medical Inc. seller in Q1 2018 was Invesco, an estimated $41.5M sold.

Based on aggregated 13F filings for Q1 2018.